Lawson Kroeker Investment Management Inc. NE Buys 13,566 Shares of Enovis Corporation $ENOV

Key Points

• Lawson Kroeker Investment Management Inc. NE increased its stake in Enovis Corporation by 6.3% during Q2, acquiring an additional 13,566 shares, bringing its total to 227,235 shares valued at approximately $7.1 million.
• Analysts have lowered price targets for Enovis, with notable firms like Evercore ISI and Wells Fargo reducing targets to $46.00 and $41.00, respectively, while maintaining "outperform" and "overweight" ratings.
• Institutional investors currently hold 98.45% of Enovis stock, indicating strong institutional confidence in the company despite a recent decline in its stock price.

Lawson Kroeker Investment Management Inc. NE raised its stake in Enovis Corporation (NYSE:ENOV - Free Report) by 6.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 227,235 shares of the company's stock after buying an additional 13,566 shares during the period. Enovis accounts for 1.3% of Lawson Kroeker Investment Management Inc. NE's holdings, making the stock its 24th largest holding. Lawson Kroeker Investment Management Inc. NE owned approximately 0.40% of Enovis worth $7,126,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Humankind Investments LLC lifted its stake in shares of Enovis by 8.6% in the 1st quarter. Humankind Investments LLC now owns 5,688 shares of the company's stock valued at $217,000 after acquiring an additional 452 shares during the last quarter. US Bancorp DE increased its holdings in Enovis by 2.5% in the 1st quarter. US Bancorp DE now owns 19,031 shares of the company's stock worth $727,000 after purchasing an additional 462 shares in the last quarter. Leisure Capital Management raised its position in Enovis by 2.2% in the first quarter. Leisure Capital Management now owns 22,903 shares of the company's stock valued at $875,000 after purchasing an additional 489 shares during the last quarter. Wedge Capital Management L L P NC boosted its stake in shares of Enovis by 0.3% during the second quarter. Wedge Capital Management L L P NC now owns 162,977 shares of the company's stock valued at $5,111,000 after purchasing an additional 498 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in shares of Enovis by 266.7% during the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after purchasing an additional 536 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ENOV shares. Evercore ISI dropped their price objective on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Wells Fargo & Company decreased their price target on shares of Enovis from $48.00 to $41.00 and set an "overweight" rating for the company in a research report on Friday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enovis in a research note on Wednesday. Needham & Company LLC reduced their price objective on shares of Enovis from $57.00 to $49.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Finally, UBS Group decreased their price objective on Enovis from $65.00 to $57.00 and set a "buy" rating for the company in a report on Friday, August 8th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $51.00.

Enovis Trading Down 5.4%

ENOV opened at $29.69 on Friday. The company has a fifty day moving average price of $30.50 and a two-hundred day moving average price of $31.78. Enovis Corporation has a 1-year low of $25.47 and a 1-year high of $49.83. The company has a market cap of $1.70 billion, a P/E ratio of -2.08 and a beta of 1.69. The company has a current ratio of 2.25, a quick ratio of 1.15 and a debt-to-equity ratio of 0.53.

Enovis (NYSE:ENOV - Get Free Report) last issued its earnings results on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company had revenue of $383.81 million for the quarter. Analysts predict that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Insiders Place Their Bets

In other Enovis news, CEO Damien Mcdonald bought 6,457 shares of the business's stock in a transaction dated Thursday, September 11th. The shares were purchased at an average price of $30.97 per share, for a total transaction of $199,973.29. Following the purchase, the chief executive officer directly owned 102,753 shares of the company's stock, valued at approximately $3,182,260.41. This represents a 6.71% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Bradley J. Tandy acquired 3,200 shares of the business's stock in a transaction on Friday, August 22nd. The stock was acquired at an average cost of $31.41 per share, for a total transaction of $100,512.00. Following the transaction, the senior vice president owned 43,515 shares of the company's stock, valued at approximately $1,366,806.15. The trade was a 7.94% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 12,157 shares of company stock valued at $374,760. Corporate insiders own 2.70% of the company's stock.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.